• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Here's Why I'm a Buyer of Grove Inc

GRVI caters to multiple market segments like Beauty, Pet Care, Botanical Health & Wellness, Rare Cannabinoids, and even trade shows.
By TIMOTHY COLLINS
Aug 25, 2021 | 03:08 PM EDT
Stocks quotes in this article: GRVI

I've been trying to find something less noticed in the hemp, CBD, and Nutraceutical space. I've already got a few Canadian names along with some MSOs, but now I'm adding another name to the list: Grove Inc  (GRVI) .

This vertically integrated company came public only a few months ago so I won't be splashing a chart on the screen. It doesn't look that great on the daily front anyhow. What that means is someone should like the story here if they plan to scoop up some shares. And, maybe, consider legging into the position.

Unlike competitors, Grove began a multi-tier approach to its business operations from very early on. There are five components to this:

  • Automated Low-Cost Manufacturing
  • Wholesale Sales
  • Private Label Offerings
  • In-house Brands
  • On-Site Fulfillment

This pertains to the hemp product and plant-based vitamin markets. And this is a strong and growing market, as evidenced by the company's financials.

Last month the company announced preliminary fourth quarter and full-year financial results. Management projects revenues between $10.1 million and $10.4 million, an increase of over 300% year-over-year. Even more impressive is the net income expectations of $1.5 million to $2 million, reversing a $700,000 loss from a year earlier. Full year net income in the range of $2 million to $2.5 million is a huge turnaround from a $5 million loss in 2020. That's what happens when revenue climbs from $7.4 million to approximately $23.75 million in a single year. These results even surpassed Grove's internal projections.

Furthermore, they invested in and own facilities that allow for automated production equipment. This creates the ability to produce consistent results, keep costs down, and produce in large capacities. All of this results in lower pricing abilities, which helps Grove compete in the wholesale markets. Additionally, Grove offers customers respected third party lab tests to assure quality. Trust matters as much as price. Pair that with a two day or less turnaround time on orders and you'll understand why revenues are growing so quickly.

Grove provides customers with the opportunity to private label CBD and Botanical offerings. They make formulations in all categories for clients. These creations add research and development fees to Grove's top line.

The company also organized CBD.io, the largest hemp convention in the world. I can't think of a better way to create leads and bring new business in the door. The best part about it is Grove gets paid to do so. From this, they can draw both revenue and transition clients to use the Grove platform. During COVID, the company expanded CBD.io into an online marketplace where its customers could sell their white label product and get help from Grove in multiples areas like creation, manufacturing, and selling. 

Grove offers its own brands direct-to-consumer. Since they are vertically integrated there is no middleman to slow delivery or weigh on pricing. These brands include Qubes, CBD Infusionz, grn, and Zest. To compliment these, Grove recently acquired VitaMedica. This purchase opens up the enormous nutraceuticals market. VitaMedica sells multiple supplements in the nutraceuticals space, including:

  • Health & Wellness
  • Skin & Beauty
  • Surgery & Recovery

This acquisition is immediately accretive to both the top and bottom line of the company. Put everything together and Grove caters to multiple market segments like Beauty, Pet Care, Botanical Health & Wellness, Rare Cannabinoids, and even trade shows.

The overall diversity of the revenue model paired with the vertical integration has me thinking this will be a double-digit stock by next summer. I'm a buyer.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Timothy Collins was Long GRVI.

TAGS: Investing | Stocks | Trading | Pets | Consumer Products | Cannabis

More from Investing

Lopsided Market Returns

James "Rev Shark" DePorre
Jun 5, 2023 4:22 PM EDT

Despite the intraday reversal in Apple, Microsoft, Alphabet, Amazon, and Tesla, all helped the Nasdaq 100 outperform the other indexes as the small caps disappointed.

The Charts -- and the Data -- Support Datadog

Bruce Kamich
Jun 5, 2023 3:35 PM EDT

Here's how DDOG is emerging from a base formation.

Time for Profit-Taking on Palantir

Bruce Kamich
Jun 5, 2023 3:06 PM EDT

Here's my updated look at the charts of Palantir Technologies.

How to Trade MongoDB After Its Huge Upside Move

Bruce Kamich
Jun 5, 2023 1:45 PM EDT

Let's check out the charts and indicators for clues.

This Value Portfolio of Lovable Losers Is Down But Not Out

Jonathan Heller
Jun 5, 2023 1:10 PM EDT

With about six months to go, anything can happen for the 2023 Tax Loss Selling Recovery Portfolio.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:19 PM EDT CHRIS VERSACE

    AAP Podcast: This Company Is Not Going 'Solo'

    Listen in as I talk with the very diversified Solo...
  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login